Quantification of BCR-ABL transcripts in peripheral blood cells and plasma of chronic myeloid leukemia patients at different stages of tyrosine kinase inhibitor treatment response
Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for blood cell sampling for quantification of breakpoint cluster region-Abelson oncogene (BCR-ABL) transcript levels to monitor treatment responses in chronic myeloid leukemia (CML) patients.
Methods: Peripheral blood samples were collected from 20 healthy individuals and 165 CML patients at various stages of treatment response. Level of BCR-ABL mutation gene transcripts were determined by RNA extraction and quantitative real time polymerase chain reaction (RT-PCR).
Results: The ratio of BCR-ABL transcripts/ABL transcripts in blood cells was significantly higher (p < 0.05) than in plasma for untreated and treated patients. Patients who received tyrosine kinase inhibitor (TKI) therapy and achieved major molecular response during treatment had the lowest mean ratio detected in blood cells (0.06 ± 0.0 %) and the ratio was below the detectable limit in plasma samples. Unlike plasma samples, BCR-ABL/ABL transcript ratios in blood cell samples strongly correlated with white cell counts in CML patients undergoing all types of treatment responses.
Conclusion: Blood cell sampling is more sensitive than plasma sampling in diagnosis and evaluation of CML treatment response.
Keywords: Chronic myeloid leukemia, Peripheral blood cells, Plasma RNA, Treatment response, Tyrosine kinase inhibitors
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.